FDA Approves Capivasertib Pill for Common Breast Cancer

For years, patients with a common form of breast cancer have watched treatments arrive slowly, each one a small step. On November 15, a new drug entered the fight. The FDA approved capivasertib, to be sold as Truqap, for a specific group of patients: those with hormone receptor-positive, HER2-negative breast cancer. It is an oral medication, taken by pill. That alone changes things for patients who dread infusion chairs.

This is not a standalone therapy. Capivasertib is approved for use alongside fulvestrant, an older drug that blocks estrogen. Together, they target a cancer subtype that accounts for roughly 70% of all breast cancers. The HR+, HER2- designation means the cancer cells have receptors for hormones like estrogen or progesterone, but lack the HER2 protein. That distinction matters. It determines who qualifies for the new regimen.

The FDA called capivasertib a first-in-class medication. That label means it works differently from anything else on the market. It belongs to a new class of drugs, with a mechanism of action that is unique. For oncologists, that opens a fresh line of attack against a disease that finds ways to survive older treatments.

The side effect list is long. Diarrhea tops it. Skin reactions follow. Lab values shift: glucose rises, lymphocytes and hemoglobin drop. Nausea, fatigue, vomiting, stomatitis — the list reads like a catalog of chemotherapy misery. But these are the known costs. The FDA approved the drug anyway, which suggests the benefit outweighed the risk for the trial patients. Doctors will have to monitor blood work closely. Patients will need support for the gastrointestinal and skin effects.

The approval came in November 2023. That timing matters. Breast cancer research has accelerated in the last decade, but the HR+, HER2- subtype has lagged behind triple-negative and HER2-positive cancers in new drug development. Capivasertib closes part of that gap. It offers a new option for patients whose disease has progressed on endocrine therapy — the standard first-line treatment.

What led here? Years of research into the PI3K/AKT pathway, a signaling chain that cancer cells hijack to grow. Capivasertib blocks AKT, a protein in that chain. By cutting that signal, the drug starves the cancer of growth instructions. It is a targeted approach, not a scattergun. That precision is what earned it the first-in-class designation.

The approval is not a cure. No one is claiming that. It is a new tool, one that extends the timeline for patients who have run out of standard options. The combination with fulvestrant gives oncologists a two-pronged attack: block the hormone signal with fulvestrant, cut the growth signal with capivasertib. For patients with advanced or metastatic disease, that could mean months of stable disease or tumor shrinkage.

The drug will be sold under the brand name Truqap. The company that developed it has not announced pricing. That will matter. New cancer drugs often carry six-figure annual price tags. Insurance coverage and patient assistance programs will determine who actually gets the drug.

For now, the approval stands as a milestone. A new class of drug. A new oral option. A new combination for a common cancer. The side effects are real. The monitoring burden is real. But for patients who have watched their tumors grow through every available treatment, a real option is better than none.